6-piperidinocarbostyril | 116942-29-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-piperidinocarbostyril
• 英文别名: 2(1H)-Quinolinone, 6-(1-piperidinyl)-；6-piperidin-1-yl-1H-quinolin-2-one
• CAS: 116942-29-1
• 化学式: C₁₄H₁₆N₂O
• 分子量: 228.294
• InChiKey: CRKAFKVYTPNDMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-piperidinocarbostyril 生成 6-哌啶-1-基-1H-喹啉-2-酮盐酸盐
  参考文献：
  名称：

  6-piperidyl carbostyril compounds and compositions containing them

  摘要：

  本发明涉及式（I）的化合物及其酸加盐。本发明还涉及将式（I）的化合物及其药学上可接受的酸加盐作为哺乳动物中的正性肌力药物的用途。

  公开号：

  US04937248A1
• 作为产物：
  描述：

  6-氨基-2(1H)-喹啉酮 以45的产率得到6-piperidinocarbostyril
  参考文献：
  名称：

  6-piperidyl carbostyril compounds and compositions containing them

  摘要：

  本发明涉及式（I）的化合物及其酸加盐。本发明还涉及将式（I）的化合物及其药学上可接受的酸加盐作为哺乳动物中的正性肌力药物的用途。

  公开号：

  US04937248A1

文献信息

• Quinoline compound
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0272910B1

  公开（公告）日：1991-08-07
• TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090053168A1

  公开（公告）日：2009-02-26

  The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.
• COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090047243A1

  公开（公告）日：2009-02-19

  The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.
• BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：RICKLES Richard

  公开号：US20100009934A1

  公开（公告）日：2010-01-14

  The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in amounts that together are effective to treat the B-cell proliferative disorder. The invention further features pharmaceutical compositions and kits including a BAR agonist, alone or in combination with additional agents, for the treatment of a B-cell proliferative disorder.
• Compositions, Methods, and Kits for Treating Influenza Viral Infections
  申请人：Altmeyer Ralf

  公开号：US20110028510A1

  公开（公告）日：2011-02-03

  The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).